Bristol Myers Squibb suspends autoimmune CAR-T trials after severe side effects emerge
Bristol Myers Squibb halted its CAR-T trials for autoimmune diseases after life-threatening side effects were observed, coinciding with three deaths in similar Novartis studies.
In early June, Bristol Myers Squibb announced a pause to its CAR-T therapy trials aimed at autoimmune disorders after severe adverse events surfaced. The suspension was revealed alongside reports of three fatalities in comparable Novartis trials, prompting scrutiny over trial transparency. Regulators, researchers and patient groups were notified of the halt, highlighting safety challenges in emerging cell-based treatments.
Why it matters
The pause delays promising autoimmune therapies and highlights safety-transparency gaps in cutting-edge cell treatments.
In this story
